Overview
- Researchers at IDIBELL report in Nature Aging that Rhosin, a small-molecule RhoA inhibitor, rejuvenates hematopoietic stem cells ex vivo and in vivo, restoring nuclear organization and improving blood and immune regeneration after transplantation.
- An analysis highlighted by Cell describes aged Cynomolgus primates receiving biweekly infusions of human mesenchymal stem cells engineered to enhance FOXO3 over ten months, showing multi-organ rejuvenation signals including brain, bone, inflammatory, and reproductive markers.
- The primate study indicates benefits were mediated largely by exosomes released from the modified cells, and exosome-only administration reproduced many effects, pointing to a potentially more controllable strategy than live-cell therapy.
- Both lines of work build on past setbacks for mesenchymal stem cell therapies and now shift attention toward paracrine signaling and pharmacological targeting rather than long-term engraftment or cell replacement.
- Key uncertainties persist on durability, long-term safety, molecular drivers such as specific exosome cargo, and human responsiveness, and the IDIBELL team has initiated patent steps as experts call for rigorous clinical trials and oversight.